Attached files
| file | filename |
|---|---|
| 8-K/A - 8-K/A - MEDICINES CO /DE | form8-karecothrom.htm |
| EX-99.3 - EXHIBIT - MEDICINES CO /DE | exhibit993recothrom.htm |
| EX-99.2 - EXHIBIT - MEDICINES CO /DE | exhibit992recothrom.htm |
| EX-99.4 - EXHIBIT - MEDICINES CO /DE | exhibit994recothrom.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in the Registration Statements (Forms S-8 No. 333-44884, 333-74612, 333-98191, 333-116295, 333-135460, 333-135461, 333-148602, 333-152105, 333-157499, 333-161672, 333-167895, 333-167896) pertaining to the 1998 Stock Incentive Plan, the 2000 Outside Director Stock Option Plan, the 2000 Employee Stock Purchase Plan, the 2001 Non-Officer, Non Director Employee Stock Incentive Plan, the 2004 Stock Incentive Plan, the 2007 Equity Inducement Plan, the 2009 Equity Inducement Plan, the Amended and Restated 2004 Stock Incentive Plan, and the 2010 Employee Stock Purchase Plan of The Medicines Company and Registration Statement (Form S-3 No. 333-139987) of our report dated February 7, 2013, relating to the statement of net revenues and direct expenses of the U.S. business of Recothrom, which is a product line of the Bristol-Myers Squibb Company, for the year ended December 31, 2011, included in this Current Report on Form 8-K/A of The Medicines Company.
/s/ Deloitte & Touche LLP
Parsippany, NJ
April 19, 2013